Nanotech test for Alzheimer's on the horizon
This article was originally published in Clinica
Executive Summary
US researchers have devised a nanotechnology-based technique that could detect the onset of Alzheimer's disease, much earlier than current methods allow. Called bio barcode amplification (BCA), the technology works by measuring, in human cerebrospinal fluid (CSF), ultra-low levels of amyloid beta-derived diffusible ligands (ADDLs) - a biomarker linked to the development of the condition.